In a dramatic departure from its traditional focus on calorie counts and group considerations, weight watchers have announced a new strategic partnership in Great Britain with Chequp, a provider of GLP-1 weight loss medication such as Wegovy and Mounjaro.
The move marks a large shift for the legendary brand, which now matches the booming market for injections against the access.
The partnership takes place only a few weeks after the weight monitors in the USA submitted insolvency protection in Chapter 11, a step that is driven by increasing debts and a declining customer base, since more people are more of medication than the food plans for weight loss.
As part of the agreement, CHEEP patients receive GLP-1 medication to an individual version of the weight watchman app, which was specially developed for the support of weight loss injections. The platform offers professional recommendations for food that aims to reduce side effects such as nausea and at the same time promote healthy, sustainable weight loss.
“The data is clear – our members on obese medications that also take part in our program for nutritional and behavioral life lose average 11% more weight than those who use the medication alone,” said Scott Honken, Chief Commercial Officer at weight protocol.
The company, which was renamed in 2018, once boasted celebrity supporters like Oprah Winfrey, who became his best-known lawyer and shareholder. But at the beginning of this year, Winfrey announced that it would leave the company and donate its shares, shortly after he reveals that its own weight loss was achieved by using medication against the adjekt-amendment from WWS points-based program.
The step to take weight loss medication is an important pivot point for weight guards, a brand that has been synonymous with non -medical behavioral approaches for a diet for decades. Its structured food plans, branded cookbooks, already meals and community-based meetings were once the focus of the global movement for weight loss. The landscape has changed the increasing demand for prescription injections – supported by clinical studies that show considerable weight loss.
GLP-1 drug such as Semaglutid (Wegven) and Tirzepatid (Mounjaro) quickly transform how both patients and providers approach obesity. Despite the recent enthusiasm, studies have also shown that the weight returns as soon as the medication is stopped, unless long-term changes in the lifestyle-a gap weight observer must be filled.
“There is no doubt that the addition of the breakthrough of weights increases the breakthrough of the GLP 1 accompanying program for the ability of our patients to achieve sustainable weight loss,” said James Hunt, deputy CEO of Chequp. “It combines scientifically supported tools with a global community of like -minded people.”
The British partnership reflects a similar strategy that is introduced in the United States because the weight monitors mean their future to become the lifestyle partner of the global weight loss drug industry, which offers coaching, nutritional advice and behavior support for patients who now choose medication towards food plans.
While the GLP-1 drug recording in Great Britain remains limited compared to the United States, obesity experts have asked the NHS to accelerate access to the treatments in order to assume the growing obesity crisis in Great Britain-with increasing cases of diabetes, cancer and cardiovascular diseases.
When the company is rejecting its legacy diet model, Weilwatchers plays that his next chapter is not to tell people what to eat, but to support them with the right tools and the right community.
It remains to be seen whether this reinvention will be sufficient to revive the assets of the brand, but one thing is clear: the weight guards have officially entered the age of the weight loss.